Conglomerate of Rheumatology and Spondylitis Organizations Released New Updated Guidelines Against Mandatory Switching to Biosimilars

• The new updated guidelines are being built on previous recommendations based on best practices for imaging, managing biologic and biosimilars usage in patients, and providing information on new medication
• The guidelines included 20 clinical questions based on pharmacological treatment indicated in 2015 guidelines and 26 new question on the pharmacological treatment treat-to-target strategy, and use of imaging in addition to separate voting panel and recommendations were labeled
• Additionally, the guidelines also included recommendation against mandatory switching to biosimilar as a first anti-TNF treatment in patients whose disease is still active as the biosimilar will have the same response as the original one

Click here to read full press release/ article | Ref: American College of Rhuematology | Image: Behance